Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal antibody isatuximab to the VRd regimen would reduce the risk of disease progression or death among patients ineligible to undergo transplantation is unclear. METHODS: In an international, open-label, phase 3 trial, we randomly assigned, in a 3:2 ratio, patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation to receive either isatuximab plus VRd or VRd alone. The primary efficacy end point was progression-free survival. Key secondary end points included a complete response or better and minimal residual disease (MRD)-negative status in patients with a complete response. RESULTS: A total of 446 patients underwent randomization. At a median follow-up of 59.7 months, the estimated progression-free survival at 60 months was 63.2% in the isatuximab-VRd group, as compared with 45.2% in the VRd group (hazard ratio for disease progression or death, 0.60; 98.5% confidence interval, 0.41 to 0.88; P<0.001). The percentage of patients with a complete response or better was significantly higher in the isatuximab-VRd group than in the VRd group (74.7% vs. 64.1%, P = 0.01), as was the percentage of patients with MRD-negative status and a complete response (55.5% vs. 40.9%, P = 0.003). No new safety signals were observed with the isatuximab-VRd regimen. The incidence of serious adverse events during treatment and the incidence of adverse events leading to discontinuation were similar in the two groups. CONCLUSIONS: Isatuximab-VRd was more effective than VRd as initial therapy in patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation. (Funded by Sanofi and a Cancer Center Support Grant; IMROZ ClinicalTrials.gov number, NCT03319667.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Isatuximab plus VRd (Isa-VRd) has also shown impressive results in newly diagnosed myeloma.102,103”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [102]
Citations
Cites
1 retracted
Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2016) · Leukemia · doi:10.1038/leu.2015.240 · Cited by 219
RetractedKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationDaratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045
Self-citationDaratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Self-citationMoreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 967
Self-citationDurie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
Self-citationDaratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312054 · Cited by 599
Self-citationMunshi, N. C., Avet-Loiseau, H., Rawstron, A. C., Owen, R. G., Child, J. A., Thakurta, A., Sherrington, P., Samur, M. K., Georgieva, A., Anderson, K. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3160 · Cited by 532
Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00466-6 · Cited by 370
Self-citationMultiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 355
Multiple myeloma: patient outcomes in real‐world practice
Yong, K., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McQuire, S., Safaei, R., Karlin, L., Mateos, M., Raab, M. S., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14213 · Cited by 326
New criteria for response assessment: role of minimal residual disease in multiple myeloma
Paiva, B., van Dongen, J. J. M., & Orfao, A. (2015) · Blood · doi:10.1182/blood-2014-11-568907 · Cited by 299
Kumar, S. K., Jacobus, S. J., Cohen, A. D., Weiss, M., Callander, N., Singh, A. K., Parker, T. L., Menter, A., Yang, X., Parsons, B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30452-6 · Cited by 245
Self-citationLeypoldt, L. B., Tichy, D., Besemer, B., Hänel, M., Raab, M. S., Mann, C., Munder, M., Reinhardt, H. C., Nogai, A., Görner, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01696 · Cited by 168
Self-citationGoldschmidt, H., Mai, E. K., Bertsch, U., Fenk, R., Nievergall, E., Tichy, D., Besemer, B., Dürig, J., Schroers, R., von Metzler, I., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00263-0 · Cited by 160
Self-citationFonseca, R., Usmani, S. Z., Mehra, M., Slavcev, M., He, J., Cote, S., Lam, A., Ukropec, J., Maiese, E. M., Nair, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07503-y · Cited by 127
Multiple myeloma: practice patterns across Europe
Raab, M. S., Cavo, M., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McQuire, S., Safaei, R., Karlin, L., Mateos, M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14193 · Cited by 112
Gay, F., Roeloffzen, W. W. H., Dimopoulos, M. A., Rosiñol, L., van der Klift, M., Mina, R., Oriol, A., Katodritou, E., Wu, K. L., Rodríguez‐Otero, P., et al. (2023) · Blood · doi:10.1182/blood-2023-177546 · Cited by 99
Self-citationHow I treat multiple myeloma in geriatric patients
Facon, T. T. F., Leleu, X. P., & Manier, S. (2023) · Blood · doi:10.1182/blood.2022017635 · Cited by 79
Self-citationVerelst, S. G. R., Blommestein, H. M., de Groot, S., Gonzalez‐McQuire, S., DeCosta, L., de Raad, J. B., Groot, C. A. U., & Sonneveld, P. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000045 · Cited by 57
Bruno, A. S., Willson, J., Opalińska, J., Nelson, J. J., Lunacsek, O. E., Stafkey-Mailey, D., & Willey, J. P. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1800451 · Cited by 50
Harrison, S. J., Perrot, A., Alegre, A. M., Simpson, D., Wang, M. C., Spencer, A. G., Delimpasi, S., Hulin, C., Sunami, K., Facon, T. T. F., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17499 · Cited by 50
Self-citationZweegman, S., Usmani, S. Z., Chastain, K. M., Carey, J., Ren, K., Smith, E. M., Krevvata, M., Wang, J., VERMEULEN, J. T., & Facon, T. T. F. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps8056 · Cited by 35
Self-citationOcio, E. M., Perrot, A., Bories, P., Miguel, J. F. S., Blau, I. W., Karlin, L., Martínez‐López, J., Wang, S., Bringhen, S., Marcatti, M., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01936-7 · Cited by 35
Self-citationTargeting CD38 alleviates tumor-induced immunosuppression
Tai, Y., & Anderson, K. C. (2017) · Oncotarget · doi:10.18632/oncotarget.22992 · Cited by 29
Špıčka, I., Moreau, P., Martin, T. G., Facon, T. T. F., Martınez, G., Oriol, A., Koh, Y., Lim, A. B. M., Mikala, G., Rosiñol, L., et al. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13835 · Cited by 24
Self-citationMateos, M., Paiva, B., Romero, M. T. C., Puig, N., Sureda, A. M., Oriol, A., Ocio, E. M., Rosiñol, L., Montes, Y. G., Bargay, J., et al. (2023) · Blood · doi:10.1182/blood-2023-179866 · Cited by 24
Cited by
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
CAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens-Arias, V., Diaz-Beya, M., Juan, M., Urbano-Ispizua, Á., Esteve, J., Velasco-Hernandez, T., & Menéndez, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 281
Dimopoulos, M. A., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M.-V., Zweegman, S., Cook, G., Engelhardt, M., Delforge, M., Hajek, R., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01041-x · Cited by 165
“75 .”
Self-citationUsmani, S. Z., Facon, T. T. F., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M. J., Pour, L., Martí, J. M., Basu, S., Cohen, Y. C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03485-7 · Cited by 206
“The median Daratumumab is a human immunoglobulin (Ig)Gκ monoclonal antibody targeting CD38 with direct on-tumor 1–4 and immunomodulatory 5–7 mechanisms of action that has demonstrated overall survival benefit in three frontline regimens 8–10 and was the first anti-CD38 monoclonal antibody approved in newly diagnosed m…”
InfluentialSelf-citationDaratumumab or active monitoring for high-risk smoldering multiple myeloma
Dimopoulos, M. A., Voorhees, P. M., Schjesvold, F., Cohen, Y. C., Hungria, V., Sandhu, I., Lindsay, J., Baker, R. I., Suzuki, K., Kosugi, H., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409029 · Cited by 121
Self-citation
Metadata
- Authors
- Facon, T., Dimopoulos, M.-A., Leleu, X. P., Beksac, M., Pour, L., Hájek, R., Liu, Z., Minarik, J., Moreau, P., Romejko-Jarosinska, J., Spicka, I., Vorobyev, V. I., Besemer, B., Ishida, T., Janowski, W., Kalayoglu-Besisik, S., Parmar, G., Robak, P., Zamagni, E., Goldschmidt, H., Martin, T. G., Manier, S., Mohty, M., Oprea, C., Brégeault, M.-F., Macé, S., Berthou, C., Bregman, D., Klippel, Z., & Orlowski, R. Z.
- Affiliations
- Inserm (FR)
- From the Department of Hematology, Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Lille (T.F., S. Manier), the French National Academy of Medicine (T.F.), and the Department of Hematology, Hôpital Saint-Antoine, Sorbonne University and INSERM (M.M.), Paris, Service d’Hématologie et Thérapie Cellulaire, CHU and Centre d’Investigation Clinique INSERM Unité 1402, Poitiers (X.P.L.), the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.), and Sanofi, Research and Development, Vitry-sur-Seine (C.O., M.-F.B., S. Macé, C.B.) — all in France; the Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens (M.-A.D.); the Department of Hematology, Ankara University, and the Istinye University Ankara Liv Hospital, Ankara (M.B.), and the Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul (S.K.-B.) — all in Turkey; the Department of Internal Medicine, Hematology, and Oncology, Uni...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-31
- Volume
- 391
- Issue
- 17
- Pages
- 1597-1609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399304831
- Semantic Scholar
- a45e6cd60318735bf0f85aba849da20117440058
- Cited by
- 284
- References
- 30
- Citations by year
- 2026: 100 · 2025: 155 · 2024: 29
- FWCI
- 87.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- isatuximab, bortezomib, lenalidomide, dexamethasone, multiple myeloma, newly diagnosed multiple myeloma, anti-CD38 monoclonal antibody, progression-free survival, complete response, minimal residual disease, transplant-ineligible patients, first-line therapy
- MeSH terms
- Bortezomib, Lenalidomide, Progression-Free Survival, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm, Residual, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.